Anika Therapeutics ANIK Note And Royalty Receivable Noncurrent
Note And Royalty Receivable Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept anik:NoteAndRoyaltyReceivableNoncurrent.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's note and royalty receivable noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's note and royalty receivable noncurrent?
- Anika Therapeutics (ANIK) reported note and royalty receivable noncurrent of $5.68M in Q1 2026.
- How has Anika Therapeutics's note and royalty receivable noncurrent changed year-over-year?
- Anika Therapeutics's note and royalty receivable noncurrent decreased by 2.7% year-over-year, from $5.84M to $5.68M.
- What does note and royalty receivable noncurrent mean?
- This metric represents the long-term portion of financial assets owed to the company arising from contractual royalty agreements or long-term notes receivable. It captures future economic benefits expected to be collected beyond the next twelve months, typically resulting from licensing intellectual property or divestiture arrangements. Monitoring this balance provides insight into the company's long-term revenue streams derived from non-core operations or historical asset sales.